Literature DB >> 17681650

A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector.

Da-Hai Yu1, Min Li, Xi-Dan Hu, Hong Cai.   

Abstract

We examined the immunogenicity and protective efficacy of a combined DNA vaccine that included six genes encoding immunodominant antigens from Mycobacterium tuberculosis and Brucella abortus. The IL-12 adjuvant system was used for immunization in combination with the combined DNA vaccine (DNA-IL-12(+)). Mice immunized with DNA-IL-12(+) had significantly reduced CFU counts for M. tuberculosis and B. abortus in lung and spleen, respectively (P<0.001), and DNA-IL-12(+) elicited better protection than the combined DNA vaccine alone (DNA-IL-12(-)) or with the positive control groups after challenge with a virulent M. tuberculosis strain and B. abortus 2308 infection. The DNA-IL-12(+) group had stronger antigen-specific IFN-gamma ELISPOT activities and higher levels of antigen-specific CD4(+) and CD8(+) T cell responses than either the DNA-IL-12(-) or positive control groups. Likewise, antigen-specific IgG titers were also much higher than in other immunized groups. Moreover, DNA-IL-12(+) gave a stronger IgG2a-skewed response than did DNA-IL-12(-). In addition, its mean concentrations of IFN-gamma and IL-2 were about 2.5- to 4.5-fold higher than those observed in the DNA-IL-12(-)-treated mice, and were significantly higher than control groups (P<0.01 or P<0.001), whereas IL-4 and IL-10 secretion were lower. These results suggest that IL-12 acts as an adjuvant to enhance protective immunity against M. tuberculosis and B. abortus through the induction of stronger Th1-associated immune responses. This is the first report to show that a single combined DNA vaccine protects animals against two infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681650     DOI: 10.1016/j.vaccine.2007.06.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Authors:  Ying Xu; Wei Liu; Hongbo Shen; Jingran Yan; Di Qu; Honghai Wang
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

2.  TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro.

Authors:  Jia-Yun Li; Yuan Liu; Xiao-Xue Gao; Xiang Gao; Hong Cai
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

3.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

4.  Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Authors:  Nicola J Commander; James M Brewer; Brendan W Wren; Stephen A Spencer; Alastair P Macmillan; Judith A Stack
Journal:  Genet Vaccines Ther       Date:  2010-07-16

Review 5.  Recent advances in Brucella abortus vaccines.

Authors:  Elaine M S Dorneles; Nammalwar Sriranganathan; Andrey P Lage
Journal:  Vet Res       Date:  2015-07-08       Impact factor: 3.683

6.  Immune Response of Calves Vaccinated with Brucella abortus S19 or RB51 and Revaccinated with RB51.

Authors:  Elaine M S Dorneles; Graciela K Lima; Andréa Teixeira-Carvalho; Márcio S S Araújo; Olindo A Martins-Filho; Nammalwar Sriranganathan; Hamzeh Al Qublan; Marcos B Heinemann; Andrey P Lage
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

Review 7.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.

Authors:  Kai Ling Chin; Fadhilah Zulkipli Anis; Maria E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  J Immunol Res       Date:  2017-06-20       Impact factor: 4.818

8.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06

Review 9.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.